MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/16078454.2022.2108902

Медицинская библиотека · Hematology (Amsterdam, Netherlands) · 2022

JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?

Tarantini Francesco, Cumbo Cosimo, Zagaria Antonella, Parciante Elisa, Anelli Luisa, Coccaro Nicoletta, Tota Giuseppina, Minervini Crescenzio Francesco, Redavid Immacolata, Rossi Antonella Russo, Conserva Maria Rosa, Specchia Giorgina, Musto Pellegrino, Albano Francesco

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.

METHODS

BCR-ABL1 molecular monitoring was performed by real-time quantitative PCR (RQ-PCR). At the time of molecular relapse, a targeted next-generation sequencing analysis with a customized panel of 26 genes commonly mutated in myeloid diseases was performed. To investigate the kinetics of the JAK2 variant and its association with the BCR-ABL1 rearrangement, RQ-PCR was performed at different time points during the patient's follow-up.

RESULTS

While negative at CML diagnosis, the JAK2 mutation was first detected 9 years later (VAF: 7.2%). The mutational burden of JAK2 remained stable in multiple determinations, with minor fluctuations independent of BCR-ABL1 kinetics. At the last available time point, the patient was in deep molecular response (MR4), the JAK2 mutational burden was 7%, and no clinical-laboratory findings of Ph-MPN were detectable.

DISCUSSION: In the presented case, the JAK2variantoccurring during the course of the disease seems to stay in the shadows of CML, just as a bystander. The impact of this event (that may be considered suggestive of clonal hematopoiesis of indeterminate potential) on the disease outcome, even if seemingly irrelevant, has still to be explored.

Для цитирования: Tarantini Francesco, Cumbo Cosimo, Zagaria Antonella, Parciante Elisa, Anelli Luisa, Coccaro Nicoletta, Tota Giuseppina, Minervini Crescenzio Francesco, Redavid Immacolata, Rossi Antonella Russo, Conserva Maria Rosa, Specchia Giorgina, Musto Pellegrino, Albano Francesco. JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?. Hematology (Amsterdam, Netherlands). 2022. DOI: 10.1080/16078454.2022.2108902.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.